South Korea
· Delayed Price · Currency is KRW HYUNDAI BIOLAND Statistics
Total Valuation
HYUNDAI BIOLAND has a market cap or net worth of KRW 132.30 billion. The enterprise value is 121.02 billion.
| Market Cap | 132.30B |
| Enterprise Value | 121.02B |
Important Dates
The next estimated earnings date is Wednesday, February 4, 2026.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
HYUNDAI BIOLAND has 30.00 million shares outstanding. The number of shares has increased by 0.36% in one year.
| Current Share Class | 30.00M |
| Shares Outstanding | 30.00M |
| Shares Change (YoY) | +0.36% |
| Shares Change (QoQ) | -0.98% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.80% |
| Float | 19.50M |
Valuation Ratios
The trailing PE ratio is 10.68 and the forward PE ratio is 7.23.
| PE Ratio | 10.68 |
| Forward PE | 7.23 |
| PS Ratio | 1.02 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | 8.39 |
| P/OCF Ratio | 6.57 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.78, with an EV/FCF ratio of 7.68.
| EV / Earnings | -38.55 |
| EV / Sales | 0.93 |
| EV / EBITDA | 5.78 |
| EV / EBIT | 7.75 |
| EV / FCF | 7.68 |
Financial Position
The company has a current ratio of 3.51, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.51 |
| Quick Ratio | 1.60 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | 0.67 |
| Interest Coverage | 31.77 |
Financial Efficiency
Return on equity (ROE) is 8.79% and return on invested capital (ROIC) is 5.96%.
| Return on Equity (ROE) | 8.79% |
| Return on Assets (ROA) | 5.44% |
| Return on Invested Capital (ROIC) | 5.96% |
| Return on Capital Employed (ROCE) | 11.15% |
| Revenue Per Employee | 380.29M |
| Profits Per Employee | -9.21M |
| Employee Count | 341 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.52 |
Taxes
In the past 12 months, HYUNDAI BIOLAND has paid 1.84 billion in taxes.
| Income Tax | 1.84B |
| Effective Tax Rate | 12.86% |
Stock Price Statistics
The stock price has increased by +3.90% in the last 52 weeks. The beta is 0.83, so HYUNDAI BIOLAND's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | +3.90% |
| 50-Day Moving Average | 4,536.10 |
| 200-Day Moving Average | 4,630.40 |
| Relative Strength Index (RSI) | 50.05 |
| Average Volume (20 Days) | 60,223 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HYUNDAI BIOLAND had revenue of KRW 129.68 billion and -3.14 billion in losses. Loss per share was -104.24.
| Revenue | 129.68B |
| Gross Profit | 56.06B |
| Operating Income | 15.61B |
| Pretax Income | 14.28B |
| Net Income | -3.14B |
| EBITDA | 20.95B |
| EBIT | 15.61B |
| Loss Per Share | -104.24 |
Balance Sheet
The company has 21.83 billion in cash and 10.55 billion in debt, giving a net cash position of 11.28 billion or 376.11 per share.
| Cash & Cash Equivalents | 21.83B |
| Total Debt | 10.55B |
| Net Cash | 11.28B |
| Net Cash Per Share | 376.11 |
| Equity (Book Value) | 137.95B |
| Book Value Per Share | 4,584.00 |
| Working Capital | 64.87B |
Cash Flow
In the last 12 months, operating cash flow was 20.13 billion and capital expenditures -4.37 billion, giving a free cash flow of 15.77 billion.
| Operating Cash Flow | 20.13B |
| Capital Expenditures | -4.37B |
| Free Cash Flow | 15.77B |
| FCF Per Share | 525.53 |
Margins
Gross margin is 43.23%, with operating and profit margins of 12.03% and -2.42%.
| Gross Margin | 43.23% |
| Operating Margin | 12.03% |
| Pretax Margin | 11.01% |
| Profit Margin | -2.42% |
| EBITDA Margin | 16.15% |
| EBIT Margin | 12.03% |
| FCF Margin | 12.16% |
Dividends & Yields
This stock pays an annual dividend of 35.00, which amounts to a dividend yield of 0.80%.
| Dividend Per Share | 35.00 |
| Dividend Yield | 0.80% |
| Dividend Growth (YoY) | 100.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.36% |
| Shareholder Yield | 0.43% |
| Earnings Yield | -2.37% |
| FCF Yield | 11.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | May 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HYUNDAI BIOLAND has an Altman Z-Score of 5.53 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.53 |
| Piotroski F-Score | 5 |